On May 6, 2026, Dallah Healthcare Company announced the execution of a binding share sale and purchase agreement to sell its entire 31.21% shareholding in Dr. Mohammed Bin Rashed Al Fagih & Partners Company to Dr. Soliman Abdel Kader Fakeeh Hospital Co. for SAR 497,983,407. The transaction is part of a larger deal where the buyer will acquire 100% of Mohammed AlFagih Co. for a total consideration of SAR 1,595,625,000, subject to regulatory approvals and other conditions precedent that must be satisfied within six months. Dallah Healthcare plans to use the proceeds primarily to reduce its current Murabaha facilities to improve financial leverage and support its growth strategy of focusing on directly operated and fully owned assets. The transaction is expected to have a material positive financial impact through capital gains and reduced financing costs, with completion contingent upon satisfying various conditions including competition authority approval.

Original announcement:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.